文献速递眼底病与葡萄膜炎

视网膜厚度波动与抗VEGF治疗nAMD的视力和解剖结局关联

Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti-Vascular Endothelial Growth Factor Agents.
PubMed 文献 · JAMA Ophthalmol · 2020-01-01

基于CATT和IVAN随机临床试验的事后分析,纳入1731只未治疗过的nAMD眼,按FCPT标准差四分位分组,发现FCPT波动越大,24个月时BCVA越差,且纤维化和黄斑萎缩风险越高。

要点

  • FCPT波动最大组比最小组BCVA多下降6.27个ETDRS字母。
  • FCPT波动增大与纤维化和黄斑萎缩风险增加相关。
  • 即使按方案治疗,视网膜厚度波动仍与更差结局相关。

核心结论

  • 抗VEGF治疗nAMD期间视网膜厚度波动越大,BCVA越差且纤维化和黄斑萎缩风险越高。

研究设计与样本

  • 基于CATT和IVAN随机临床试验的事后分析,纳入1731只未治疗过的nAMD眼。
  • 从CATT的1165只眼和IVAN的566只眼中提取FCPT,排除测量≤3次的眼。

主要发现

  • FCPT标准差中位数(IQR)在IVAN队列为40.2(27.1-61.2),在CATT队列为59.0(38.3-89.4)。
  • 校正基线BCVA和试验分配后,BCVA随FCPT标准差四分位显著恶化,第一与第四四分位差为-6.27个ETDRS字母(95%CI -8.45至-4.09)。
  • 纤维化风险随FCPT标准差四分位增加,OR从第二四分位的1.40(95%CI 1.03-1.91)到第四四分位的1.95(95%CI 1.42-2.68)。
  • 黄斑萎缩风险随FCPT标准差四分位增加,OR从第二四分位的1.32(95%CI 0.90-1.92)到第四四分位的2.10(95%CI 1.45-3.05)。

临床怎么用

  • 在向患者说明预后时,可考虑视网膜厚度波动情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: When initiating anti-vascular endothelial growth factor (VEGF) treatment for patients with neovascular age-related macular degeneration (nAMD), knowledge of prognostic factors is important for advising patients and guiding treatment. We hypothesized that eyes with greater fluctuation in retinal thickness over time have worse outcomes than eyes with less variation. OBJECTIVE: To investigate whether visual and anatomic outcomes in eyes with nAMD initiating anti-VEGF treatment are associated with fluctuations in retinal thickness. DESIGN, SETTING, AND PARTICIPANTS: In this study using data from the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) and the Inhibition of VEGF in Age-Related Choroidal Neovascularization (IVAN) randomized clinical trial, people with previously untreated nAMD were included. Data were collected from February 2008 to November 2012, and data were analyzed from April 2017 to April 2020. MAIN OUTCOMES AND MEASURES: Foveal center point thicknesses (FCPTs) were extracted from 1165 study eyes from CATT and 566 study eyes from the IVAN trial, excluding those with 3 measurements or less. For each eye, the SD of FCPT was calculated. Eyes were grouped by FCPT SD quartile. Associations of FCPT SD quartile with outcomes were quantified at month 24 or the last available visit by linear or logistic regression, adjusting for baseline best-corrected visual acuity (BCVA) and randomized allocations to drug and treatment regimen, for BCVA, development of fibrosis, and development of macular atrophy. RESULTS: Of the 1731 included patients, 1058 (61.1%) were female, and the mean (SD) age was 78.6 (7.4) years. The median (interquartile range) FCPT SD was 40.2 (27.1-61.2) in the IVAN cohort and 59.0 (38.3-89.4) in the CATT cohort. After adjustment for baseline BCVA and trial allocations, BCVA worsened significantly across the quartiles of FCPT SD; the difference between the first and fourth quartiles was -6.27 Early Treatment Diabetic Retinopathy Study letters (95% CI, -8.45 to -4.09). The risk of developing fibrosis and macular atrophy also increased across FCPT SD quartiles. Odds ratios ranged from 1.40 (95% CI, 1.03 to 1.91) for quartile 2 to 1.95 (95% CI, 1.42 to 2.68) for quartile 4 for fibrosis and from 1.32 (95% CI, 0.90 to 1.92) for quartile 2 to 2.10 (95% CI, 1.45 to 3.05) for quartile 4 for macular atrophy. CONCLUSIONS AND RELEVANCE: Greater variation in retinal thickness in eyes with nAMD during treatment with anti-VEGF was associated with worse BCVA and development of fibrosis and macular atrophy in these post hoc analyses, despite protocol-directed treatment frequency. Practitioners may want to consider variation in retinal thickness when advising patients about their prognosis.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Evans RN, Reeves BC, Maguire MG, et al. Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti-Vascular Endothelial Growth Factor Agents. JAMA Ophthalmol. 2020. PMID: 32816002. doi:10.1001/jamaophthalmol.2020.3001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。